UNH - UnitedHealth Group Incorporated
| Previous Close | 265.96 |
| Open | 265.33 |
| Bid | 265.28 x 1100 |
| Ask | 265.37 x 1000 |
| Day's Range | 263.19 - 266.41 |
| 52 Week Range | 208.07 - 287.94 |
| Volume | 1,313,498 |
| Avg. Volume | 5,311,369 |
| Market Cap | 252.358B |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | 20.62 |
| EPS (TTM) | 12.88 |
| Earnings Date | Jul 18, 2019 |
| Forward Dividend & Yield | 4.32 (1.62%) |
| Ex-Dividend Date | 2019-06-14 |
| 1y Target Est | 287.74 |
- Zacks•1 hour ago
The Zacks Analyst Blog Highlights: JP Morgan, UnitedHealth, Lockheed Martin and BHP Billiton
The Zacks Analyst Blog Highlights: JP Morgan, UnitedHealth, Lockheed Martin and BHP Billiton
- Simply Wall St.•2 hours ago
Is Now The Time To Put UnitedHealth Group (NYSE:UNH) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Market Realist•3 hours ago
Will UnitedHealth Group Report Strong Q2 Earnings?
On Thursday, UnitedHealth Group (UNH) is scheduled to release its second-quarter earnings. The company will release its earnings before the market opens.
- MarketWatch•5 hours ago
UnitedHealth stock has bounced back after a rough first quarter. Will its positive streak continue?
Investors are keeping an eye on UnitedHealth’s earnings report, which often acts as a bellwether for investor sentiment for the sector for rest of the earnings season.
- Zacks•5 hours ago
UnitedHealth (UNH) to Report Q2 Earnings: What's in Store?
UnitedHealth's (UNH) second-quarter results are expected to be boosted by the revenue growth at UnitedHealthcare and Optum segments and increasing membership.
- Investor's Business Daily•22 hours ago
These Stocks Are Unlike The Others; Can You Profit From Them?
This year's stock market rally left out the health care sector and XLV ETF. But is this an opportunity? Johnson & Johnson and UnitedHealth earnings are due.
- Zacks•yesterday
Dow ETF Appears Strong Ahead of Q2 Earnings
With most blue-chip companies' earnings scheduled over the coming weeks and investors' sentiment being mixed, investors should closely monitor the movement of the Dow ETF.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Microsoft, UnitedHealth, Costco, Uber and Microchip Technology
The Zacks Analyst Blog Highlights: Microsoft, UnitedHealth, Costco, Uber and Microchip Technology
- Zacks•yesterday
Is UnitedHealth Group (UNH) Outperforming Other Medical Stocks This Year?
Is (UNH) Outperforming Other Medical Stocks This Year?
- MarketWatch•yesterday
Earnings Watch: Expect drama in second-quarter numbers as trade fears weigh
Second-quarter earnings are usually pretty sleepy, with forecasts for the back-to-school and holiday periods tucked away for later review amid summer vacation schedules. You may want to pay attention this year, though.
- InvestorPlace•yesterday
CVS Stock Is a Buy as It Prepares to Take on Private Insurance
Since July of 2016 CVS Health (NYSE:CVS) has been a nightmare for investors. This time three years ago, CVS stock traded at a little more than $97, today it trades at something closer to $57.Source: Shutterstock Despite making what seemed like smart moves, like dropping cigarettes, converting to a health format, adding clinics, and buying Aetna, the stock has continued to sink.But analysts have suddenly warmed to CVS' story. In the last month, the shares are up 8%. On July 11 alone they rose 4.68%. Even at that price, CVS is still selling at a retailer's multiple of less than half its revenue.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt's an illustration of the difference between the marketplace and the stock market. It's a great opportunity for investors with a long-term view. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond Chronic Conditions and CVS StockAmerica spends 18% of its GDP on health care, but 75% of that is spent treating and monitoring chronic conditions. These are preventable diseases like heart disease, diabetes, and kidney disease.This is what CVS has been focused on. By delivering services as well as products through almost 10,000 stores, the company hopes to gain a bigger share of this $1.1 trillion bonanza. Preventing obesity, treating alcoholism and ending smoking could be worth trillions more.Analysts have been focusing on drugs, in the form of Amazon (NASDAQ:AMZN) and its Pillpack service or CVS' Caremark Pharmacy Benefit Manager, but CVS has been diversifying away from the pure-intermediary model.Aetna alone brings 22 million insurance accounts to the party. If CVS' network can reduce the costs of covering those people, it can offer lower prices that increase that number. That's what its HealthHUB strategy is all about.Deliver the most common services and treatments from a storefront, add front-line clinics for primary care, of which CVS already has 1,100, and you have more cost control than any insurance rival. CVS hopes to turn 1,500 of its outlets into HealthHubs in the next two years. CVS Stock and the Real CompetitionCVS' rivals in this area aren't Amazon or even Walgreens Boots Alliance (NYSE:WBA). They're other insurers like United Healthcare (NYSE:UNH), which dominates the private insurance market and managed care companies like Centene (NYSE:CNC), which uses company-owned facilities to handle Medicare and Medicaid at a profit.Investors haven't credited any of CVS' moves for political reasons. Democrats talking about converting all health care to a publicly funded system makes them nervous. The possible end of Obamacare, pricing tens of millions out of the insurance market, also makes them nervous.But CVS' strategy can work in either case. If Democrats expand Medicare the companies that can cut costs fastest will benefit. If people are left without insurance, stores that offer the lowest-cost primary care and services grow. The Bottom Line on CVS StockIn its first-quarter report for 2020, delivered May 1, CVS earned $1.4 billion, $1.62 per share fully diluted, on revenues of $61.6 billion. This is the first fiscal year that has begun since the Aetna deal closed. CVS raised earnings guidance for the full year. Its 50 cent per share dividend, with its fat 3.6% yield, is thus affordable.Because of its retail operation, CVS is the only insurer that can rival United Healthcare in size. That company's revenues for the first quarter were $60.3 billion. It has four times the market share of Aetna in private insurance.Most analysts consider United Healthcare the biggest winner in health care, but macro trends may be running against it. CVS stock is a winner for income investors right now, with that fat, affordable dividend.Dana Blankenhorn is a financial and technology journalist. He is the author of a new environmental story, Bridget O'Flynn and the Bear, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in AMZN and CVS. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post CVS Stock Is a Buy as It Prepares to Take on Private Insurance appeared first on InvestorPlace.
- MarketWatch•yesterday
Health companies start reporting earnings next week: Here are 3 things to keep in mind
Health companies will begin reporting second-quarter earnings next week, starting with two Dow components, Johnson & Johnson and UnitedHealth Group Inc. It has been a tumultuous few months for managed-care companies, pharmaceutical companies and biotechs. UnitedHealth (UNH) , facing investor anxiety about the implementation a single-payer system, saw its shares drop sharply in April even after the company beat Wall Street expectations and boosted full-year guidance.
- TheStreet.com•yesterday
4 Earnings Reports to Watch This Week
There are a lot of earnings releases scheduled for this week from big names companies. Charles Schwab stock has had a rough run of it this year. It's a fascinating turn of events, as the company actually has some of the best annual growth rates that you'll find in terms of revenue and earnings growth.
- Zacks•4 days ago
Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback
Cigna's (CI) Pharmacy Benefits management is poised to gain due to the pullback of the drug rebate proposal.
- Zacks•4 days ago
Is UnitedHealth (UNH) Stock a Buy Heading into Q2 2019 Earnings?
Shares of UnitedHealth Group (UNH) popped Friday after they surged Thursday to help spur the Dow Jones Industrial Average's rally. But should investors consider buying UNH stock ahead of its Q2 earnings results?
- Zacks•4 days ago
ETFs to Shine as Trump Tosses Drug Rebate Curb Plan
We study the impact of Trump's dropping of the proposed drug rebate rule on some health ETFs with exposure to pharmacy benefit managers and healthcare insurers.
- Zacks•4 days ago
Top Analyst Reports for Microsoft, UnitedHealth & Costco
Top Analyst Reports for Microsoft, UnitedHealth & Costco
- Yahoo Finance•4 days ago
Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump
Ruud Dobber, AstraZeneca’s biopharmaceuticals president, weighs in on the Trump administration walking back one change it had been seeking in the drug space.
- Zacks•4 days ago
Dow Breezes Past 27,000: 4 Blue-Chip Stocks to Buy
The 30-stock index closes above the 27,000 mark for the first time. It took nearly 372 days for the blue-chip index to cross the 27,000 mark from when it reached the 26,000 mark in January 2018.
- Investor's Business Daily•4 days ago
Dow Jones Leads Stocks Higher; UnitedHealth, Amazon Stock Rise
UnitedHealth led among Dow Jones stocks Friday, as the Dow and S&P; 500 added to unusually strong mid-month gains for July.
- Zacks•4 days ago
Health Insurers Rejoice on Pullback of Drug Rebate Plan
After many regulatory disturbances and overhang of the drug rebate ban proposal, a repeal of it is a breather for health insurers.
- Market Realist•4 days ago
This Rebate Decision Saw Health Insurers Soar Yesterday
On Thursday, the Trump administration announced the withdrawal of the proposal to abolish rebates paid to pharmacy benefit managers by drugmakers.
- Zacks•4 days ago
Dow 30 Stock Roundup: Cisco to Buy Acacia, Microsoft & ServiceNow Partnernership
The index endured a turbulent week but gained after the Fed Chair indicated that a rate was likely later this month.
- InvestorPlace•4 days ago
3 Big Stock Charts for Friday: HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals
Another win for the market on Thursday, with the S&P 500 ending the session up 0.23% to finish the session at just a hair below 3,000. The volume grew once again on the third-straight daily gain, though it is still below average.Source: Shutterstock CVS Health (NYSE:CVS) and UnitedHealth Group (NYSE:UNH) ranked among the session's biggest winners, up 4.7% and 5.5%, respectively, after President Trump decided to not enact new rules that would stymie rebates on pharmaceutical purchases. At the other end of the spectrum, Merck (NYSE:MRK) led the losers on Thursday, as the President's move worried some that it could end up being pharmaceutical companies that bore the brunt of any cost-control initiatives. Merck shares ended the day down by 4.5%. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond Headed into the final trading day of the week, though, it's HollyFrontier (NYSE:HFC), Activision Blizzard (NASDAQ:ATVI) and Vertex Pharmaceuticals (NASDAQ:VRTX) that merit the closest looks from traders. Here's why, and what to look for.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals is still technically in a long-term uptrend, guided higher by a rising support line that extends all the way back to late-2017. Although it has ebbed and flowed along the way, it has made higher highs and higher lows for some time now.The flavor of the advance changed in a fundamental way this year, however, and although it has been more erratic than not, current and prospective owners may want to note that the repeated bearish swings are taking a cumulative toll on the broad uptrend. Click to Enlarge * Chief among the changes in the timbre of the major rally is the fact that for the first time in several quarters, VRTX has logged a streak of lower highs. They're plotted in yellow on both stock charts. * The long-term support line is marked with a dashed blue line on both charts. * It's easy to look past in the wide swings we've seen since the beginning of 2018, but the most recent round of weakness has pulled the purple 50-day moving average line below the white 200-day line for the first time since mid-2018 (although that instance proved to be a great entry point). HollyFrontier (HFC)Late last month, HollyFrontier shares were able to punch through a long-standing falling resistance line, and proceed to test their 100-day moving average line, marked in gray on both stock charts. That test ultimately failed, sending HFC lower again. Shares only needed to take a small step back before renewing a much-needed running start. The second effort made a big dent on Thursday. * 7 Marijuana Stocks With Critical Levels to Watch Click to Enlarge * The resistance line in question is marked in yellow on both stock charts. In retrospect, May's steep selloff served as the capitulation the chart needed. * Although it faltered the first time when attempting to push past the moving average line (highlighted), Thursday's second attempt worked nicely. * While the volume behind the runup since May's bottom is on reasonably healthy volume, the pace hasn't been healthy. HollyFrontier isn't yet stochastically overbought, but it's getting to that point fast. Activision Blizzard (ATVI)Finally, within nothing more than a quick glance, Activision Blizzard shares merely look stuck in a trading range. And, that may well be the case. A deeper look at some of the more subtle clues, however, suggests the bulls may be working on a bigger-picture recovery of last year's oversized pullback. The inflection point is within sight too, with a massive amount of room to run if and when the last hurdle area is cleared. Click to Enlarge * The subtle hints are not just the bullish crosses of most of the moving average lines on the daily chart. Since the end of last month, the 20-, 50- and 100-day moving average lines are acting as support. * The inflection point, or final potential resistance, is the 200-day moving average line at $51, plotted in white on both stock charts. In the meantime, there's horizontal resistance around $48.80. * The weekly chart puts the potential rebound in perspective. It also better identifies the fact that we've already seen a higher low.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post 3 Big Stock Charts for Friday: HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals appeared first on InvestorPlace.
- Zacks•5 days ago
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
